Loading...
Immune checkpoint inhibitors targeting PD-1 have been shown to improve response, progression-free survival, and overall survival when combined with first-line chemotherapy in patients with metastatic esophagogastric cancer. Investigators in China now report results of ORIENT-16, an industry-sponsored, randomized, double-blind, placebo-controlled trial evaluating the addition of sintilimab to first-line chemotherapy in patients with advanced esophagogastric adenocarcinoma. Patients received capecitabine and oxaliplatin every 3 weeks combined with either placebo or sintilimab (3 mg/kg in patients <60 kg or 200 mg in patients >60 kg) for up to six cycles.
Of the 650 patients enrolled, 81% had gastric primary tumors, 39% had liver metastases, an…